Passage Bio, Inc., a clinical-stage biotechnology firm based in Philadelphia, United States, has recently experienced a notable shift in analyst sentiment following its latest earnings report. The company, which specializes in developing gene therapies for rare central nervous system and neuromuscular disorders, reported a quarterly loss that exceeded consensus expectations. This financial outcome has prompted several research houses to adjust their outlooks on the company.
Wall Street Zen, a prominent research firm, downgraded Passage Bio from a “sell” to a “strong sell” rating. This downgrade reflects growing concerns about the company’s near-term financial performance and the progress of its lead programs. Other analysts have also adjusted their positions, moving from “strong-buy” or “buy” to “hold” or “neutral” ratings. Consequently, the consensus price target for Passage Bio has been trimmed, indicating a more cautious view of the stock’s upside potential.
Despite these challenges, institutional investors continue to hold a significant stake in Passage Bio. The company’s market capitalization stands at $18,733,616 USD, with a close price of $5.84 as of April 23, 2026. Over the past year, the stock has experienced volatility, reaching a 52-week high of $20 on January 8, 2026, and a 52-week low of $5.124 on July 20, 2025. The price-to-earnings ratio is currently at -0.404, reflecting the company’s ongoing financial losses.
Passage Bio, Inc. operates in the health care sector and is listed on the Nasdaq exchange. The company focuses on developing a portfolio of AAV-delivered therapeutics aimed at treating rare monogenic central nervous system diseases. Its primary market is within the state of Pennsylvania, although its impact and reach extend beyond this region through its innovative gene therapy programs.
For more detailed information about Passage Bio’s activities and offerings, stakeholders and interested parties can visit the company’s website at www.passagebio.com or access investor relations channels through the Nasdaq stock exchange. As Passage Bio navigates its current financial and operational challenges, it remains committed to advancing its therapeutic pipeline and addressing the unmet needs of patients with rare genetic disorders.
